Latest filing published 03 Apr 2024 for Black Diamond Therapeutics, Inc., €14k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Wendy l. Dixon (board member) discloses dealings in 5 companies, chiefly Black Diamond Therapeutics, Inc., Incyte Corp and Alkermes plc. We count 22 filings; the first trade dates from 20 May 2021 and the latest from 15 March 2024.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The record was last updated on 3 April 2024 with a share grant (€14k) in Black Diamond Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations